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INTRODUCTION: Use of inorganic mercury compounds in cosmetic products is prohibited as it 
can cause significant nephrotoxicity. However, the public continues to have access to these illegal 
products in Hong Kong.  
 
MATERIAL AND METHODS: This is a retrospective study aiming to evaluate the clinical 
characteristics and the treatment outcome of inorganic mercury poisoning due to the use of beauty 
cream. Cases were identified using the electronic system of the Hong Kong Poison Information 
Centre from 2008-2015. Only those with proven inorganic mercury poisoning and prior use of 
beauty cream were included. 
 
RESULTS: 17 patients were included in the analysis. 88.2% were female and more than half of 
those were Indonesian. Most of the patients were treated with dimercaptosuccinic acid chelation, 
prednisolone or combination therapy. Baseline 24-hour urine mercury levels correlate with the 
severity of proteinuria (Pearson’s correlation 0.587, p=0.035). Compared to chelation therapy alone, 
combination therapy with prednisolone demonstrated statistical significant reduction in urine 
protein levels (99.41±0.11vs. 98.73±0.19; p=0.015).  
 
CONCLUSIONS: Inorganic mercury poisoning due to the use of beauty cream causes minimal 
change disease, resulting in nephrotic syndrome. Baseline 24-hour urine mercury level correlates 
with the severity of proteinuria. Statistical significant reduction in proteinuria was found in patients 
receiving combination therapy with dimercaptosuccinic acid and prednisolone.  
 
Table 1. Baseline characteristics of the patients according to different treatment regimens 
 
 No DMSA and 
Prednisolone 
DMSA only Prednisolone 
only 
Prednisolone + 
DMSA 
N 3 3 2 7 
Age 47 (33-64) 32 (23-38) 39 (18) 29 (22-57) 
Female (%) 3 (66.7%) 5 (100%) 1 (50%) 7 (100%) 
Cumulative dose of 
DMSA (mg) 
N/A 15004±1.5 N/A 23976±1.4 
Cumulative dose of 
Prednisolone (mg) 
N/A N/A 2874±3.0 1627±3.4 
Spot blood mercury level 
(nmol/L) 
80.2±9.4 103.8±3.9 80.6±1.7 49.6±1.4 
24 hour urine mercury 
level (nmol/day) 
24.3±1.9 514.9±3.1 127.2±12.0 204.2±2.9 
24 hour urine protein level 
(g/day) 
3.69±1.61 7.70±1.65 7.86±1.45 10.53±1.29 
 
